


place this application in better condition for examination and to correct a clerical error in the specification.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made".

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By 
Roger L. Browdy
Registration No. 25,618

RLB:rd

Telephone No.: (202) 628-5197

Facsimile No.: (202) 737-3528

G:\bN\q\qBI\einat1.1D\pto\PrelimAmendA.doc

Version with Markings to Show Changes Made

In the Specification:

Paragraph 16 has been rewritten as follows:

[0016] Figure 2 is a computer scan showing RTP801 (SEQ ID NO:1) Northern blot analysis. RNA was extracted from Rat C6 glioma cells which were exposed to hypoxia for 0, 4, or 16 hours. PolyA+ selected mRNA (2 µg) from each sample were separated on denaturing agarose gels, blotted onto Nytran membranes and hybridized with RTP241-RTP801 probe. One band of 1.8 Kb is observed showing a marked induction after hypoxia.

In the Claims:

Claims 2, 3, 8, 9, and 12 have been amended as follows:

2 (Amended). An isolated nucleic acid molecule in accordance with claim 1 comprising a sequence encoding a polypeptide having ~~an~~ the amino acid sequence ~~selected from the group consisting of~~ SEQ ID NO:9.

3 (Amended). An isolated nucleic acid molecule in accordance with claim 1 comprising a sequence encoding a polypeptide having ~~an~~ the amino acid sequence ~~selected from the group consisting of~~ SEQ ID NO:10.

8 (Amended). An antibody in accordance with claim 7 which specifically binds to a polypeptide having ~~an~~ the amino

acid sequence ~~selected from the group consisting of~~ SEQ ID NO:9.

9 (Amended). An antibody in accordance with claim 7 which specifically binds to a polypeptide having ~~an~~ the amino acid sequence ~~selected from the group consisting of~~ SEQ ID NO:10.

12 (Amended). A method for the treatment of a subject in need of treatment for hypoxia or ischemia-related disease comprising administering to said subject a therapeutically effective amount of an antagonist of a ~~protein~~ polypeptide having a sequence as set forth in SEQ ID NO:10, or an analogue thereof.